Tiziana Life Sciences Ltd 6-K, filed Jul 15, 2022
Tiziana Life Sciences Ltd (TLSA)
About this 6-K
Tiziana Life Sciences Ltd filed this 6-K on July 15, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
July 2022
Commission File Number: 0001723069
Tiziana Life Sciences Ltd.
(Exact Name of Registrant as Specified in Its Charter)
9th Floor
107 Cheapside
London
EC2V 6DN
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On July 11, 2022, Dr. Kunwar Shailubhai, the Chief Executive Officer and Chief Scientific Officer of Tiziana Life Sciences Ltd. (the “Company”), tendered his resignation as Chief Executive Officer, Chief Scientific Officer and director to the Board of Directors for personal reasons, effective August 1, 2022. Gabriele Cerrone, Executive Chairman of the Board, has been appointed as interim Chief Executive Officer. The Company issued a press release dated July 15, 2022 with respect to this event.
The press release is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.
|
Exhibit Index | |
| Exhibit No. | |
| 99.1 | Tiziana Life Sciences Ltd. Press Release dated July 15, 2022 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| TIZIANA LIFE SCIENCES LTD | |||
| Date: July 15, 2022 | By: | /s/ Keeren Shah | |
| Name: | Keeren Shah | ||
| Title: | Finance Director | ||
3
Exhibit 99.1
Tiziana Life Sciences Announces Resignation of CEO
New York, July 15, 2022 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that the Board of Directors has accepted the voluntary resignation of Dr. Kunwar Shailubhai as Chief Executive Officer, Chief Scientific Officer and Board director, effective as of August 1, 2022. Dr. Shailubhai resigned for personal reasons, and his resignation is not related to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
The Board has appointed Gabriele Cerrone, Executive Chairman of Tiziana, as interim Chief Executive Officer to lead the Company through this period of transition. The Board will begin a search for a permanent Chief Executive Officer and Chief Scientific Officer immediately.
“On behalf of the Board, I want to thank Kunwar for his many years of exceptional service to Tiziana and his commitment to our vision in providing locally acting antibody therapies to patients with unmet needs,” said Gabriele Cerrone, Executive Chairman of Tiziana. “We wish Kunwar well in his future endeavors. We continue to advance our foralumab clinical development programs as planned, and will provide a progress update in due course,” he added.
About Tiziana Life Sciences
Tiziana
Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies
to enable alternative routes of immunotherapy. Tiziana’s innovative nasal, oral and inhalation approaches in development have the
potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s
two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated
a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of
immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For further inquiries:
Tiziana Life Sciences Ltd
Hana Malik, Business Development, and Investor Relations Manager +44 (0) 207 495 2379 email: info@tizianalifesciences.com
|
|
Investors: Irina Koffler LifeSci Advisors, LLC 646.970.4681 ikoffler@lifesciadvisors.com |